Status:
UNKNOWN
Comparison Of Efficacy Of Combination Of TAM Formula Vs Kligman Formula For Melasma.
Lead Sponsor:
Jinnah Postgraduate Medical Centre
Conditions:
Melasma
Eligibility:
All Genders
25-65 years
Phase:
PHASE2
Brief Summary
This study would offer the participants about the knowledge of these formula in the treatment of melasma and help the investigators in incorporating and updating the management protocols in medical pr...
Eligibility Criteria
Inclusion
- Patients between 25-65 years of age, either gender having melasma for over one month will be included in the study
Exclusion
- Pregnancy, breastfeeding, taking birth control pills or plans to become pregnant during the study
- History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis
- History of skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy
- History of uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
- History of sensitivity to hydroquinone or Retin-A
- History of evidence of a compromised immune system or hepatitis
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2023
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT06013540
Start Date
August 1 2022
End Date
August 30 2023
Last Update
August 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
JPMC
Karachi, Sindh, Pakistan